RNN Rexahn Pharmaceuticals Inc.

0.54
+0.01  (+2%)
Previous Close 0.53
Open 0.55
Price To Book 2.46
Market Cap 26154898
Shares 48,282,995
Volume 133,075
Short Ratio 0.74
Av. Daily Volume 1,133,697

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 completion of enrolment announced March 4, 2019. Completion of trial due 2H 2019.
RX-3117 in combination with Abraxane
First-line pancreatic cancer
Phase 2a updated preliminary data presented at ASCO GU February 15, 2019. 1/31 ORR/CR.
RX-3117
Bladder cancer
Phase 2 enrolment stopped - noted December 2018. Will focus on combo trial with Keytruda to be initiated 2H 2019.
RX-5902
Triple negative breast cancer
Noted February 8, 2018 that development will be discontinued.
Archexin
Renal cell carcinoma (RCC) - cancer
Phase 2 trial planned.
Archexin
Hepatocellular carcinoma (HCC)

Latest News

  1. Rexahn Pharmaceuticals Reports 2018 Financial Results
  2. Rexahn Announces Target Enrollment Reached in Phase 2a Clinical Trial of RX-3117 in Combination With ABRAXANE® in First-line Metastatic Pancreatic Cancer Patients
  3. Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors
  4. Rexahn Presents Updated Interim Data From Phase 2a Trial of RX-3117 in Advanced Bladder Cancer at the 2019 ASCO GU Symposium
  5. What You Must Know About Rexahn Pharmaceuticals, Inc.’s (NYSEMKT:RNN) Beta Value
  6. Rexahn Announces Presentations at the 2019 ASCO Genitourinary Cancers Symposium
  7. Rexahn Receives Notice of Allowance for U.S. Patent Covering RX-3117 Use in a Broad Range of Tumor Types
  8. Market Trends Toward New Normal in SeaWorld Entertainment, Rigel Pharmaceuticals, Guidewire Software, Editas Medicine, Jones Energy, and Rexahn Pharmaceuticals — Emerging Consolidated Expectations, Analyst Ratings
  9. Rexahn Announces Pricing of Public Offering of Common Stock and Warrants
  10. Rexahn Announces Proposed Public Offering of Common Stock and Warrants
  11. Rexahn Presents Updated Preliminary Data on RX-3117 in Pancreatic Cancer at the 2019 ASCO GI Symposium
  12. The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug
  13. Biotech Breaking Out
  14. Rexahn Announces Presentation of RX-3117 Data at the 2019 ASCO Gastrointestinal Cancers Symposium
  15. The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
  16. Market Trends Toward New Normal in CME Group, Ambac Financial Group, Erie Indemnity, FuelCell Energy, Hovnanian Enterprises, and Rexahn Pharmaceuticals — Emerging Consolidated Expectations, Analyst Ratings
  17. Rexahn Pharmaceuticals Streamlines Operations and Provides Update on Pipeline
  18. Rexahn Pharmaceuticals Appoints Gil Price to its Board of Directors
  19. Rexahn Pharmaceuticals Announces Leadership Transition
  20. Rexahn Reports Third Quarter 2018 Financial Results